title: Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.
abstract: There are few pharmaceuticals superior to opiates for the treatment of pain. However, with concerns of addiction, withdrawal and questionable efficacy for all types of pain, these compounds are far from a magical panacea for pain-relief. As it is unlikely that other classes of compounds will supersede the opioids in the very near future, it is important to both optimize current opioid therapies and curb the astounding diversion of opioids from their intended analgesic use to non-medical abuse. In optimizing opioid therapeutics it is necessary to enhance the clinical awareness of the benefits of treating pain and combine this with aggressive strategies to reduce diversion for non-medical use. At the heart of the issue of opioid misuse is the role of opioid systems in the reward circuitry, and the adaptive processes associated with repetitive opioid use that manifest during withdrawal. Emerging pharmacological insights of opioid receptors will be reviewed that provide future hope for developing opioid-based analgesics with reduced addictive properties and perhaps, reduced opponent processes. In addition, with the increased understanding of nociceptive circuitry and the molecules involved in transmitting pain, new therapeutic targets have become evident that may result in effective analgesics either alone or in combination with current opioid therapies.
authors.affiliation: Shirley and Stephan Hatos Center for Neuropharmacology, Semel Institute, Los Angeles, CA 90024-1759, USA. wwalwyn@ucla.edu
authors.forename: Wendy M
authors.initials: WM
authors.lastname: Walwyn
authors.forename: Karen A
authors.initials: KA
authors.lastname: Miotto
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Evans
mesh_terms: D000701:Analgesics, Opioid / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D016739:Behavior, Addictive / Q000378:metabolism / Q000523:psychology*; D006801:Humans; D009293:Opioid-Related Disorders / Q000378:metabolism / Q000523:psychology*; D010146:Pain / Q000188:drug therapy / Q000523:psychology; D011957:Receptors, Opioid / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D000701:Analgesics, Opioid; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu